Cadrenal Therapeutics(US:CVKD) Globenewswire·2026-03-12 12:00Core Insights - Cadrenal Therapeutics, Inc. is advancing its first-in-class 12-lipoxygenase (12-LOX) inhibitor, CAD-1005, which targets inflammatory consequences of obesity and Type 2 diabetes [1][2] Group 1: Scientific Findings - Recent studies indicate that CAD-1005 can delay the onset of autoimmune diabetes in non-obese diabetic mice, highlighting 12-LOX as a significant factor in obesity-related inflammation [2] - In preclinical models, CAD-1005 has shown therapeutic benefits such as improved glycemic control, reduced pancreatic β-cell loss, and lower levels of pro-inflammatory cytokines in adipose tissues [2][4] - The mechanism of 12-LOX inhibition acts as a selective "switch" to deactivate inflammatory pathways, restoring healthy metabolic signaling and protecting tissues from damage [2] Group 2: Clinical Development - CAD-1005 is also being evaluated for Heparin-Induced Thrombocytopenia (HIT), with a recent Phase 2 trial showing a reduction in thrombotic events in patients [4][7] - The drug has received Orphan Drug Designation and Fast Track designation from the U.S. FDA, as well as orphan drug status from the European Medicines Agency [7][8] Group 3: Competitive Advantage - Unlike existing treatments for obesity and diabetes, CAD-1005 specifically targets inflammatory signals in adipose tissues and the pancreas, which are key drivers of metabolic disorders [3][6] - Cadrenal believes that CAD-1005 is the only product in clinical development utilizing this mechanism to inhibit adipo-inflammatory signaling, potentially enhancing the effects of existing GLP-1 obesity medications [3][4] Group 4: Company Overview - Cadrenal Therapeutics is a late-stage biopharmaceutical company focused on developing novel therapies for life-threatening immune and thrombotic conditions [8] - The company's broader pipeline includes tecarfarin, an oral vitamin K antagonist, and frunexian, a Factor XIa inhibitor for acute hospital settings [9]